Search Results

PharmAbcine, Inc. announced that its U.S. subsidiary, Wincal Biopharm, Inc. (“WincalBio”), gained agreat attention at the world’s largest ophthalmology conference, Association for Research in Vision and Ophthalmology 2024 (ARVO 2024), when they presented the preclinical data of the eye drop formulation.

PharmAbcine, Inc. announced that the Company’s U.S. subsidiary, Wincal Biopharm, Inc., will present preclinical findings on its innovative ocular drug delivery platform at the upcoming conference, Association for Research in Vision and Ophthalmology, the world’s largest ophthalmology conference which will be held from May 5th to 9th, 2024 in Seattle, WA, United States.

PharmAbcine Inc. announces the publication of preclinical research in Science Advances, highlighting the potential of its Tie2-activating antibody program, PMC-403, in treating Idiopathic Systemic Capillary Leak Syndrome.

PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on next-generation antibody therapeutics, announced today the initiation of patient dosing in the Phase 1a/b clinical trial of PMC-309 in patients with advanced or metastatic solid tumors.

PharmAbcine Inc. announced today that the company will participate in the upcoming BIO International Convention 2023.

PharmAbcine, Inc. announced that the Safety Review Committee has approved advancing to dose level 2 of the PMC-403 Phase 1 clinical study in neovascular age-related macular degeneration patients following completion of dose level 1 safety data evaluation.

PharmAbcine Inc. announced today that the first patient has been dosed in the Phase I clinical trial of PMC-403, the Company’s novel TIE2 agonistic antibody, in nAMD (neovascular age-related macular degeneration).